Wall Street brokerages expect Heat Biologics Inc (NASDAQ:HTBX) to post earnings of ($0.06) per share for the current fiscal quarter, Zacks Investment Research reports. Three analysts have made estimates for Heat Biologics’ earnings, with the lowest EPS estimate coming in at ($0.16) and the highest estimate coming in at $0.09. Heat Biologics reported earnings of ($0.60) per share in the same quarter last year, which would indicate a positive year-over-year growth rate of 90%. The firm is scheduled to report its next earnings results on Monday, November 12th.
According to Zacks, analysts expect that Heat Biologics will report full year earnings of ($0.69) per share for the current year, with EPS estimates ranging from ($0.81) to ($0.62). For the next financial year, analysts anticipate that the business will report earnings of ($0.72) per share, with EPS estimates ranging from ($0.75) to ($0.70). Zacks’ earnings per share calculations are an average based on a survey of analysts that cover Heat Biologics.
Heat Biologics (NASDAQ:HTBX) last released its quarterly earnings data on Tuesday, August 14th. The biopharmaceutical company reported ($0.27) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.18) by ($0.09). Heat Biologics had a negative net margin of 437.62% and a negative return on equity of 116.28%. The business had revenue of $1.14 million during the quarter, compared to analyst estimates of $1.11 million.
An institutional investor recently bought a new position in Heat Biologics stock. Northern Trust Corp acquired a new position in shares of Heat Biologics Inc (NASDAQ:HTBX) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 51,512 shares of the biopharmaceutical company’s stock, valued at approximately $111,000. Northern Trust Corp owned 0.22% of Heat Biologics at the end of the most recent reporting period. Institutional investors own 4.41% of the company’s stock.
HTBX opened at $1.82 on Monday. Heat Biologics has a 12-month low of $1.09 and a 12-month high of $7.21.
Heat Biologics Company Profile
Heat Biologics, Inc, a biopharmaceutical company, focuses on developing approaches to activate and co-stimulate a patient's immune system against cancer in the United States. The company's T-cell activating platform (TCAP) produces therapies designed to turn immunologically cold tumors hot and be administered in combination with checkpoint inhibitors and other immuno-modulators to enhance clinical effectiveness.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Heat Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heat Biologics and related companies with MarketBeat.com's FREE daily email newsletter.